Idogen receives MEUR 0.55 disbursement from Horizon 2020
Idogen AB (“Idogen”) announces today that Horizon 2020, the EU programme for research and innovation, has decided to trigger a second partial payment as part of the financial support the company was granted in 2017. The payment of MEUR 0.55 has now been disbursed to Idogen and will be used to partially finance the continued development of IDO 8 – Idogen’s cell therapy project for the treatment of hemophilia A patients who have developed antibodies toward factor VIII therapy. Idogen has been awarded a research and development grant of totally MEUR 2.9, to be dispensed in several parts,